6 completed. 6 Phase 1.
By phase and status
Follow HIVAC-1e: new trials by email Literature Review of HIVAC-1e trials Research Report on HIVAC-1e
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
HIVAC-1e, gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | | 2021-10-27 |
A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
HIVAC-1e, gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 54 | | 2021-11-02 |
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | Bristol-Myers Squibb | | | 2007-09-26 |
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | | 2021-11-04 |
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | | 2021-11-04 |
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
HIVAC-1e, gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 13 | | 2021-11-02 |
Conditions studied
HIV Infections (6) · Vaccinia (6) · Acquired Immunodeficiency Syndrome (2)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Bristol-Myers Squibb (1)
Countries
United States (6)
Top investigators
Corey L (2) · Koff W (2)